ClinicalTrials.gg

Program

OLN324

A development code.

Its studies are mostly in Macular Degeneration · Diabetic Retinopathy, led by Ollin Biosciences.

Furthest: phase 3, since Sep 7, 20265 company-led studies, 4 open or runningNext primary completion: Dec 15, 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Ollin Biosciences54 open or runningphase 3since Sep 7, 2026Mar 9, 2026Dec 15, 2028phase 3 · NCT07841899

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 9, 2026First study: phase 1 study in Macular DegenerationFirst studyNCT07484074 · 164 enrolled · United States, Puerto Rico
  2. Sep 7, 20264 phase 3 studiesPhase 3 reachedNCT07842016, NCT07841899, NCT07816315 and 1 more

Ahead

  1. Dec 15, 2028Primary completion: phase 3 study in Diabetic RetinopathyNCT07842016
  2. Dec 15, 2028Primary completion: phase 3 study in Diabetic RetinopathyNCT07841899
  3. Dec 15, 2028Primary completion: phase 3 study in Macular DegenerationNCT07816315
  4. Dec 15, 2028Primary completion: phase 3 study in Macular DegenerationNCT07816289

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07842016Diabetic Retinopathy3Not yet recruitingDec 15, 2028450
NCT07841899Diabetic Retinopathy3Not yet recruitingDec 15, 2028450
NCT07816315Macular Degeneration3Not yet recruitingDec 15, 2028500
NCT07816289Macular Degeneration3Not yet recruitingDec 15, 2028400
NCT07484074Macular Degeneration · United States, Puerto Rico1CompletedOct 10, 2025164

How it is read

Names in the registry

  • “OLN324”, 5 entries

Codes read as this program: OLN324.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.